Search results
Results from the WOW.Com Content Network
The secondary structural features of IL-13 are similar to that of Interleukin 4 (IL-4); however it only has 25% sequence identity to IL-4 and is capable of IL-4 independent signaling. [ 7 ] [ 4 ] [ 8 ] IL-13 is a cytokine secreted by T helper type 2 (Th2) cells, CD4 cells, natural killer T cell , mast cells , basophils , eosinophils and ...
Activated STAT6 molecules form dimers which translocate to the nucleus to bind responsive elements (e.g. CD23 promoter in B cells, [12] arginase1 enhancer in macrophages [13]) The binding affinity of IL-4 for IL-4Rα is much higher than IL-13 for the IL-13Rα1, hence IL-4 would out-compete IL-13 for receptor availability within IL4R2 at parity ...
Rilonacept was given an orphan drug designation by the U.S. Food and Drug Administration (FDA) and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome. [3] [6] Rilonacept is the first drug approved by the FDA to treat recurrent pericarditis. [3]
For premium support please call: 800-290-4726 more ways to reach us
IL-13 is thought to induce the expression of another signalling protein, periostin, by epithelial cells of the bronchi. Periostin in turn seems to partake in a number of asthma related problems, such as bronchial hyperresponsiveness , inflammation, and activation and proliferation of airway fibroblasts , which are involved in airway remodelling.
16164 Ensembl ENSG00000131724 ENSMUSG00000017057 UniProt P78552 O09030 RefSeq (mRNA) NM_001560 NM_133990 RefSeq (protein) NP_001551 NP_598751 Location (UCSC) Chr X: 118.73 – 118.79 Mb Chr X: 35.38 – 35.43 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Interleukin 13 receptor, alpha 1, also known as IL13RA1 and CD213A1 (cluster of differentiation 213A1), is a human gene. The ...
When seeking approval for a drug, manufacturers can apply to the FDA for priority review. This is granted when a drug is intended to treat a serious condition and would "provide a significant improvement in safety or effectiveness" over currently available treatments. [1] A priority review voucher can be used when a drug does not fit these ...
Interleukin-13 receptor subunit alpha-2 (IL-13Rα2), also known as CD213A2 (cluster of differentiation 213A2), is a membrane bound protein that in humans is encoded by the IL13RA2 gene. [ 5 ] Function